Estrogen-regulated AGR3 activates the estrogen receptor signaling pathway to promote tamoxifen resistance in breast cancer

被引：0
|
作者：
Rui Jiang
Yongjie Sun
Xiao Chen
Peng Shi
机构：
[1] Shandong Provincial Hospital Affiliated to Shandong First Medical University,Department of Oncology
[2] Shandong Provincial ENT Hospital,Department of Breast and Thyroid Diseases, Shandong Second Provincial General Hospital
[3] Shandong Provincial Hospital Affiliated to Shandong First Medical University,Department of Breast and Thyroid Surgery
来源：
Breast Cancer Research and Treatment | 2021年 / 190卷
关键词：
Estrogen; AGR3; ER signaling pathway; Breast cancer; Tamoxifen resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：203 / 211
页数：8
相关论文
共 50 条
  • [31] Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
    Jeffreys, Sarah A.
    Powter, Branka
    Balakrishnar, Bavanthi
    Mok, Kelly
    Soon, Patsy
    Franken, Andre
    Neubauer, Hans
    de Souza, Paul
    Becker, Therese M.
    CELLS, 2020, 9 (09) : 1 - 23
  • [32] MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer
    Merikhian, Parnaz
    Ghadirian, Reyhane
    Farahmand, Leila
    Mansouri, Sepideh
    Majidzadeh-A, Keivan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (07) : 607 - 613
  • [33] Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer
    Boustan, Arad
    Mosaffa, Fatemeh
    Jahangiri, Rosa
    Heidarian-Miri, Hamid
    Dahmardeh-Ghalehno, Asefeh
    Jamialahmadi, Khadijeh
    MOLECULAR BIOLOGY RESEARCH COMMUNICATIONS, 2021, 10 (03) : 109 - 119
  • [34] Ceramide kinase confers tamoxifen resistance in estrogen receptor-positive breast cancer by altering sphingolipid metabolism
    Huang, Cheng
    Su, Liangping
    Chen, Yitian
    Wu, Sangqing
    Sun, Ruipu
    Xu, Qiuping
    Qiu, Xiaoyi
    Yang, Ciqiu
    Kong, Xiangzhan
    Qin, Hongquan
    Zhao, Xinbao
    Jiang, Xue
    Wang, Kun
    Zhu, Yinghua
    Wong, Ping-Pui
    PHARMACOLOGICAL RESEARCH, 2023, 187
  • [35] Crosstalk events in the estrogen signaling pathway may affect tamoxifen efficacy in breast cancer molecular subtypes
    de Anda-Jauregui, Guillermo
    Mejia-Pedroza, Raul A.
    Espinal-Enriquez, Jesus
    Hernandez-Lemus, Enrique
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2015, 59 : 42 - 54
  • [36] Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α
    Pedersen, Astrid M.
    Thrane, Susan
    Lykkesfeldt, Anne E.
    Yde, Christina W.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (05) : 2167 - 2175
  • [37] Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells
    Diao, Yumei
    Azatyan, Ani
    Rahman, Mohammed Ferdous-Ur
    Zhao, Chunyan
    Zhu, Jian
    Dahlman-Wright, Karin
    Zaphiropoulos, Peter G.
    ONCOTARGET, 2016, 7 (44) : 71580 - 71593
  • [38] Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer
    Tsoi, Ho
    Man, Ellen P. S.
    Chau, Ka Man
    Khoo, Ui-Soon
    CANCERS, 2021, 13 (07)
  • [39] Expression and clinical significance of estrogen-regulated long non-coding RNAs in estrogen receptor α-positive ovarian cancer progression
    Qiu, Jun-Jun
    Ye, Le-Chi
    Ding, Jing-Xin
    Feng, Wei-Wei
    Jin, Hong-Yan
    Zhang, Ying
    Li, Qing
    Hua, Ke-Qin
    ONCOLOGY REPORTS, 2014, 31 (04) : 1613 - 1622
  • [40] Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer
    Georgopoulos, Neoklis A.
    Adonakis, George L.
    Fotopoulos, Andreas
    Koika, Vasiliki
    Spinos, Nikitas
    Saltamavros, Alexandros
    Keramopoulos, Antonios
    Koukouras, Dimitrios
    Decavalas, George
    Kourounis, George S.
    GYNECOLOGICAL ENDOCRINOLOGY, 2006, 22 (04) : 185 - 189
12345